DelistingMay 22, 2026, 08:21 AM
Anavex Life Sciences Receives Nasdaq Delinquency Notice for Late 10-Q
AI Summary
Anavex Life Sciences Corp. received a delinquency notification from Nasdaq on May 20, 2026, for failing to timely file its Quarterly Report on Form 10-Q for the period ended March 31, 2026. This puts the company in non-compliance with Nasdaq Listing Rule 5250(c)(1). The company has until July 20, 2026, to submit a plan to regain compliance, with a potential extension until November 16, 2026. The notice does not immediately affect the trading of its common stock.
Key Highlights
- Anavex Life Sciences received a Nasdaq delinquency notice on May 20, 2026.
- The notice is due to the company's failure to timely file its Form 10-Q for the quarter ended March 31, 2026.
- This non-compliance is with Nasdaq Listing Rule 5250(c)(1).
- The company has until July 20, 2026, to submit a plan to regain compliance.
- Nasdaq may grant an exception of up to 180 days, until November 16, 2026, to regain compliance.
- The notice has no immediate effect on the listing of the company's common stock.
Price Impact
More from AVXL